Exocrine Pancreatic Insufficiency - Global Strategic Business Report

The global market for Exocrine Pancreatic Insufficiency was estimated at US$6.2 Billion in 2024 and is projected to reach US$8.7 Billion by 2030, growing at a CAGR of 5.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Exocrine Pancreatic Insufficiency market.

Global Exocrine Pancreatic Insufficiency Market - Key Trends & Drivers Summarized

What Is Exocrine Pancreatic Insufficiency and How Is It Managed?

Exocrine pancreatic insufficiency (EPI) is a condition characterized by the pancreas’ inability to produce or transport enough digestive enzymes, leading to malabsorption and digestive issues. It is commonly associated with conditions such as cystic fibrosis, chronic pancreatitis, and pancreatic cancer. Managing EPI typically involves enzyme replacement therapy (ERT), where patients take pancreatic enzyme products (PEPs) to aid digestion and improve nutrient absorption. The growing awareness and diagnosis of EPI, combined with the availability of effective enzyme replacement therapies, are driving the demand for treatments and diagnostic solutions in the market.

How Are Advancements in Diagnostic Techniques and Enzyme Formulations Impacting the Market?

Technological advancements in diagnostics and enzyme formulations have significantly impacted the exocrine pancreatic insufficiency market. Innovations in non-invasive diagnostic techniques, such as fecal elastase tests and advanced imaging technologies, enable early and accurate detection of EPI, leading to timely intervention. Moreover, pharmaceutical companies are developing advanced pancreatic enzyme formulations, including enteric-coated tablets and microencapsulated enzymes, which improve the efficacy of treatment and enhance patient compliance. These technological advancements are crucial in providing better therapeutic outcomes for patients, ensuring that treatments are both effective and convenient.

Are Regulatory Approvals and Healthcare Accessibility Influencing Market Growth?

Regulatory approvals and the accessibility of healthcare significantly influence the EPI market. The approval of new enzyme replacement therapies by regulatory bodies like the FDA and EMA has expanded treatment options, ensuring that patients have access to safe and effective therapies. Additionally, the rise of healthcare infrastructure and accessibility, especially in emerging markets, supports the diagnosis and treatment of EPI. Increased awareness campaigns by healthcare providers and pharmaceutical companies also contribute to better patient education, encouraging individuals to seek diagnosis and treatment for symptoms of EPI. These trends underscore the importance of healthcare policies and regulatory frameworks in shaping the availability and adoption of EPI therapies globally.

What Is Driving the Growth of the Exocrine Pancreatic Insufficiency Market?

The growth in the exocrine pancreatic insufficiency market is driven by several factors, including the rising prevalence of conditions such as cystic fibrosis, chronic pancreatitis, and pancreatic cancer, which are primary causes of EPI. The development of advanced pancreatic enzyme replacement therapies, designed to enhance treatment efficacy and patient compliance, further propels the market. Additionally, technological advancements in diagnostic methods facilitate early and accurate detection, encouraging timely intervention and increasing the demand for enzyme therapies. Regulatory approvals and healthcare initiatives that improve access to EPI diagnosis and treatment also play a crucial role in market growth, ensuring that patients worldwide have access to effective management solutions for exocrine pancreatic insufficiency.

SCOPE OF STUDY:

The report analyzes the Exocrine Pancreatic Insufficiency market in terms of units by the following Segments, and Geographic Regions/Countries:

• Segments: Type (Therapeutics, Diagnostics)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Therapeutics segment, which is expected to reach US$4.8 Billion by 2030 with a CAGR of a 5.5%. The Diagnostics segment is also set to grow at 6.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $1.7 Billion in 2024, and China, forecasted to grow at an impressive 5.3% CAGR to reach $1.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Exocrine Pancreatic Insufficiency Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Exocrine Pancreatic Insufficiency Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Exocrine Pancreatic Insufficiency Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie, Inc., Allergan PLC, Anthera Pharmaceuticals, Inc., AzurRx BioPharma, Inc., Cilian AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 46 companies featured in this Exocrine Pancreatic Insufficiency market report include:

• AbbVie, Inc.
• Allergan PLC
• Anthera Pharmaceuticals, Inc.
• AzurRx BioPharma, Inc.
• Cilian AG
• Digestive Care, Inc.
• Janssen Pharmaceuticals, Inc.
• Nordmark Arzneimittel GmbH & Co. KG

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.